These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 24170435)

  • 21. Effective treatment of disseminated peritoneal colon cancer with new replication-competent herpes simplex viruses.
    Kimata H; Takakuwa H; Goshima F; Teshigahara O; Nakao A; Kurata T; Sata T; Nishiyama Y
    Hepatogastroenterology; 2003; 50(52):961-6. PubMed ID: 12845959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
    Ouchi KF; Yanagisawa M; Sekiguchi F; Tanaka Y
    Cancer Chemother Pharmacol; 2006 May; 57(5):693-702. PubMed ID: 16362295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
    Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
    Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
    Wang J; Hu P; Zeng M; Rabkin SD; Liu R
    Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice.
    Chung YS; Miyatake S; Miyamoto A; Miyamoto Y; Dohi T; Tanigawa N
    Int J Oncol; 2006 Apr; 28(4):793-8. PubMed ID: 16525626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
    Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
    J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
    Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
    Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer.
    Hirooka Y; Kasuya H; Ishikawa T; Kawashima H; Ohno E; Villalobos IB; Naoe Y; Ichinose T; Koyama N; Tanaka M; Kodera Y; Goto H
    BMC Cancer; 2018 May; 18(1):596. PubMed ID: 29801474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I Dose-escalation Clinical Trial of HF10 Oncolytic Herpes Virus in 17 Japanese Patients with Advanced Cancer.
    Kasuya H; Kodera Y; Nakao A; Yamamura K; Gewen T; Zhiwen W; Hotta Y; Yamada S; Fujii T; Fukuda S; Tsurumaru N; Kuwahara T; Kikumori T; Koide Y; Fujimoto Y; Nakashima T; Hirooka Y; Shiku H; Tanaka M; Takesako K; Kondo T; Aleksic B; Kawashima H; Goto H; Nishiyama Y
    Hepatogastroenterology; 2014 May; 61(131):599-605. PubMed ID: 26176043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel genetically modified oncolytic vaccinia virus in experimental models is effective against a wide range of human cancers.
    Haddad D; Chen N; Zhang Q; Chen CH; Yu YA; Gonzalez L; Aguilar J; Li P; Wong J; Szalay AA; Fong Y
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S665-74. PubMed ID: 22258815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
    Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K
    Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
    Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
    Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer.
    Nakao A; Takeda S; Shimoyama S; Kasuya H; Kimata H; Teshigahara O; Sawaki M; Kikumori T; Kodera Y; Nagasaka T; Goshima F; Nishiyama Y; Imai T
    Curr Cancer Drug Targets; 2007 Mar; 7(2):169-74. PubMed ID: 17346108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy.
    Harsha HC; Jimeno A; Molina H; Mihalas AB; Goggins MG; Hruban RH; Schulick RD; Kamath U; Maitra A; Hidalgo M; Pandey A
    J Proteome Res; 2008 Nov; 7(11):4651-8. PubMed ID: 18821783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncolytic vaccinia virus in combination with radiation shows synergistic antitumor efficacy in pancreatic cancer.
    Dai MH; Liu SL; Chen NG; Zhang TP; You L; Q Zhang F; Chou TC; Szalay AA; Fong Y; Zhao YP
    Cancer Lett; 2014 Mar; 344(2):282-90. PubMed ID: 24321381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro and in vivo anticancer efficacy of silibinin against human pancreatic cancer BxPC-3 and PANC-1 cells.
    Nambiar D; Prajapati V; Agarwal R; Singh RP
    Cancer Lett; 2013 Jun; 334(1):109-17. PubMed ID: 23022268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
    Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma.
    Cinatl J; Cinatl J; Michaelis M; Kabickova H; Kotchetkov R; Vogel JU; Doerr HW; Klingebiel T; Driever PH
    Cancer Res; 2003 Apr; 63(7):1508-14. PubMed ID: 12670897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An oncolytic herpes simplex virus vector, G47Δ, synergizes with paclitaxel in the treatment of breast cancer.
    Zeng WG; Li JJ; Hu P; Lei L; Wang JN; Liu RB
    Oncol Rep; 2013 Jun; 29(6):2355-61. PubMed ID: 23525624
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.
    Cao C; Albert JM; Geng L; Ivy PS; Sandler A; Johnson DH; Lu B
    Cancer Res; 2006 Dec; 66(23):11409-15. PubMed ID: 17145887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.